Sigyn Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS??? DEFICIT (Details Narrative)

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)										1 Months Ended	3 Months Ended
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	Oct. 28, 2021	Oct. 25, 2021	Oct. 22, 2021	Oct. 20, 2021	Oct. 14, 2021	Jul. 14, 2021	May 10, 2021	Apr. 14, 2021	Jan. 14, 2021	Apr. 30, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Feb. 19, 2021
Preferred stock shares authorized											10,000,000		10,000,000
Preferred stock, par or stated value per share											$ 0.0001		$ 0.0001
Preferred stock, shares issued											0		0
Preferred stock shares outstanding											0		0
Common stock shares authorized											1,000,000,000		1,000,000,000
Common stock par value											$ 0.0001		$ 0.0001
Common stock shares outstanding											37,295,803		37,295,803
Debt conversion, amount							$ 110,000
Debt conversion, shares issued							157,143
Stock issued during period shares					47,000	47,000	1,172,000
Number of securities called by warrants							1,172,000
Proceeds from issuance of common stock							$ 1,465,000			$ 1,500,000
Stock issued during period value					$ 37,600	$ 47,000
Sale of stock, description										The offering allowed for qualified investors to purchase one share of the Company’s common stock $1.25. For each share purchased, the investor received a five-year warrant to purchase one share of common stock at $1.75 per share
Shares issued price per share										$ 1.25
Number of shares issued for restricted stock								47,000	47,000
Restricted stock, value								$ 82,250	$ 82,250
Previous Noteholder [Member]
Number of securities called by warrants														57,147
Convertible Promissory Note [Member]
Stock issued during period shares			450,000
Number of securities called by warrants			450,000
Proceeds from issuance of common stock			$ 197,501
Debt maturity date, description			October 20, 2021 to October 20, 2022.
Exercise price of warrants per share			$ 1.00
Other expenses											$ 48,699	$ 0
Securities Purchase Agreement [Member] \| Convertible Promissory Note [Member]
Stock issued during period shares				320,000
Number of securities called by warrants				320,000
Proceeds from issuance of common stock				$ 400,000
Debt conversion, description				The offering allowed for qualified investors to purchase one share of the Company’s common stock at $1.25. For each share purchased, the investor received a five-year warrant to purchase one share of common stock at $1.25 per share. No commissions were paid in the offering
Osher Capital Partners LLC [Member]
Debt conversion, amount	$ 16,714
Debt instrument carrying amount	$ 199,650
Debt conversion, shares issued	42,857
Osher Capital Partners LLC [Member] \| Marketing Consulting Agreement [Member]
Debt instrument carrying amount		$ 110,000
Debt conversion, shares issued		157,143